Aurobindo Pharma: US reopening, traction for COVID vaccine near-term growth opportunity

The most positive development for the last fiscal year has been a sharp reduction in leverage which positions Aurobindo Pharma for capex commitments in the API, vaccine and biosimilars space

June 02, 2021 / 12:09 AM IST
Aurobindo Pharma: US reopening, traction for COVID vaccine near-term growth opportunity

PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook

While Aurobindo Pharma (CMP: Rs 998, Market Cap: Rs 58,491 crore) reported an uninspiring result for Q4FY21, near-term triggers for the company has moved towards vaccine opportunity and the improved business dynamics in the developed world as economies open up. Vaccine opportunity This leads us to decipher the company’s earnings traction from COVID vaccine as a new facility would be ready by the end of June, and, post that, the validation process would start. The new facility would take the total...

  • PRO Panorama

    Moneycontrol Pro Panorama | The noose is tightening around Big Tech

    Jul 26, 2021 / 03:50 PM IST

    In today’s edition of Moneycontrol Pro Panorama: China’s Tibet messaging, long road ahead for Yes Bank, ITC’s ring of security, Monsoon Watch 2021, upcoming Fed policy review, mangoes and climate change, and more

    Read Now
  • PRO Weekender

    Moneycontrol Pro Weekender | Where are you on India’s wealth ladder? 

    Jul 24, 2021 / 10:00 AM IST

    The top 5 percent of Indians own more wealth than the other 95 percent put together, according to Credit Suisse

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers